Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDENV-PIV and TDENV-LAV Prime-Boost for Dengue
NCT02239614Phase 1Completed
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Dec 2014
- Primary completion
- Feb 2016
- Modality
- Live Attenuated Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TDENV-PIV and T-DEN vaccine in dengue fever (4 arms), sponsored by U.S. Army Medical Research and Development Command. Primary endpoints: Number of solicited adverse events, Number of unsolicited adverse events and 4 more. Started Dec 2014; status: completed.
02
Drugs
TDENV-PIVT-DEN vaccine
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT02239614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02239614.